Adverum Biotechnologies
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Adverum Biotechnologies generated cash of -$90,902,000, which is more than the previous year. Cash used in financing activities reached the amount of $69,000 last year. Net change in cash is therefore $6,042,000.
Cash Flow
| 2014 | -5.64M | -943K | 165.44M |
|---|---|---|---|
| 2015 | -35.33M | -41.56M | 138.86M |
| 2016 | -38.36M | 38.77M | 556K |
| 2017 | -45.42M | -122.20M | 16.74M |
| 2018 | -53.96M | 69.44M | 69.94M |
| 2019 | -49.17M | -68.07M | 28.19M |
| 2020 | -79.29M | -280.16M | 355.98M |
| 2021 | -107.83M | 78.70M | 2.39M |
| 2022 | -108.09M | 141.72M | 607K |
| 2023 | -90.90M | 96.87M | 69K |
ADVM Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 70.93M | 36.69M | 63.42M | 66.89M | 155.94M | 70.51M | 222.17M | 221.34M | 159.40M | 564K |
Operating activities | ||||||||||
Net income | -117.16M | -154.53M | -145.54M | -117.50M | -64.48M | -72.62M | -56.14M | -113.74M | -47.45M | -25.40M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 5.64M | 6.52M | 4.64M | 4.15M | 1.57M | 1.75M | 2.09M | 1.60M | 812K | 162K |
Stock-based compensation expense | 17.56M | 20.07M | 25.19M | 20.39M | 9.89M | 0 | 8.72M | 11.41M | 11.50M | 8.56M |
| Deferred income tax benefit | 17.56M | 20.07M | 25.19M | 20.39M | 9.89M | 0 | 8.72M | 11.41M | 11.50M | 8.56M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 886K | -437K | -6K | 8K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | -29K | -1.10M | 1.20M | 2.28M |
Accounts payable | -369K | 845K | -1.61M | 1.58M | -650K | -67K | 333K | -111K | -312K | -6K |
Cash generated by operating activities | -90.90M | -108.09M | -107.83M | -79.29M | -49.17M | -53.96M | -45.42M | -38.36M | -35.33M | -5.64M |
Investing activities | ||||||||||
Purchases Of Investments | -36.71M | -104.36M | -407.51M | -570.38M | -197.34M | -78.72M | -209.78M | -38.77M | -88.42M | 0 |
Investments In Property Plant And Equipment | -808K | -11.81M | -15.12M | -11.84M | -19.24M | -809K | -1.01M | -2.41M | -2.99M | -943K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.44M | 0 | 0 |
Cash generated by investing activities | 96.87M | 141.72M | 78.70M | -280.16M | -68.07M | 69.44M | -122.20M | 38.77M | -41.56M | -943K |
Financing activities | ||||||||||
Common Stock Issued | 489K | 3K | 2.63M | 344.30M | 25.88M | 70.18M | 16.51M | 0 | 138.95M | 116.45M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4M |
Repayments of term debt | 0 | 0 | -240K | -61K | -112K | -175K | 0 | 0 | 0 | 0 |
Cash used in financing activities | 69K | 607K | 2.39M | 355.98M | 28.19M | 69.94M | 16.74M | 556K | 138.86M | 165.44M |
Net Change In Cash | 6.04M | 34.23M | -26.72M | -3.47M | -89.05M | 85.42M | -151.65M | 822K | 61.94M | 158.84M |
Cash at end of period | 76.97M | 70.93M | 36.69M | 63.42M | 66.89M | 155.94M | 70.51M | 222.17M | 221.34M | 159.40M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |